ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes
-
Published:2024-08-29
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Vieira de Sá Renata, Sudria-Lopez Emma, Cañizares Luna Marta, Harschnitz OliverORCID, van den Heuvel Dianne M. A., Kling Sandra, Vonk Danielle, Westeneng Henk-Jan, Karst Henk, Bloemenkamp Lauri, Varderidou-Minasian Suzy, Schlegel Domino K.ORCID, Mars Mayte, Broekhoven Mark H., van Kronenburg Nicky C. H., Adolfs Youri, Vangoor Vamshidhar R., de Jongh RianneORCID, Ljubikj Tijana, Peeters Lianne, Seeler SabineORCID, Mocholi Enric, Basak OnurORCID, Gordon David, Giuliani Fabrizio, Verhoeff Tessa, Korsten Giel, Calafat Pla Teresa, Venø Morten T., Kjems Jørgen, Talbot KevinORCID, van Es Michael A.ORCID, Veldink Jan H.ORCID, van den Berg Leonard H., Zelina Pavol, Pasterkamp R. JeroenORCID
Funder
Adessium Foundation
Publisher
Springer Science and Business Media LLC
Reference127 articles.
1. Brown, R. H. & Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162–172 (2017). 2. van Es, M. A. et al. Amyotrophic lateral sclerosis. Lancet 390, 2084–2098 (2017). 3. Masrori, P. & Van Damme, P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 27, 1918–1929 (2020). 4. Taylor, J. P., Brown, R. H. & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206 (2016). 5. Van Damme, P., Robberecht, W. & Van Den Bosch, L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis. Model. Mech. 10, 537–549 (2017).
|
|